August 20, 2014 8:05 AM ET

Biotechnology

Company Overview of Metabolic Solutions Development Company, LLC

Company Overview

Metabolic Solutions Development Company, LLC, a drug discovery and development company, investigates novel molecular targets and develops new therapeutics to treat metabolic diseases of aging. It provides MSDC-0160 and MSDC-0602, a therapeutic agents that treats patients diagnosed with type 2 diabetes, polycystic kidney disease, and neurodegenerative diseases that include Alzheimer’s and Parkinson’s diseases; and MSDC-new chemical entities that are non-thiazolidinediones oral mitochondrial membrane modulator insulin sensitizers for the treatment of type 2 diabetes. The company was founded in 2006 and is based in Kalamazoo, Michigan.

161 East Michigan Avenue

4th Floor

Kalamazoo, MI 49007

United States

Founded in 2006

Phone:

269-343-6732

Fax:

616-940-6223

Key Executives for Metabolic Solutions Development Company, LLC

Chief Executive Officer and Member of Board of Managers
Co-Founder
Co-Founder
Chief Medical Officer
Vice President of Development
Age: 55
Compensation as of Fiscal Year 2014.

Metabolic Solutions Development Company, LLC Key Developments

Metabolic Solutions Development Company Announces Publication of Data Describing a New Drug Target for Diabetes

Metabolic Solutions Development Company announced the publication of data in the latest issue of the scientific journal PLOS ONE. on a new drug target for type 2 diabetes located in the inner mitochondrial membrane, which includes recently identified proteins that control mitochondrial pyruvate import. mTOT (mitochondrial target of thiazolidinediones) is a mitochondrial protein complex through which new anti-diabetic drugs exert their insulin sensitizing effects. Data suggest mTOT functions as a molecular sensor switch that coordinates carbohydrate, lipid, and amino acid metabolism with cell function. Recently published Phase 2b clinical data from a study in 258 type 2 diabetic patients further demonstrate modulating mTOT could constitute a new approach for the discovery and development of potentially more useful and novel insulin sensitizers. This new drug target may also play a role in other diseases of aging such as Alzheimer's disease and Parkinson's disease. Phase 2b clinical data published in the January 18, 2013 issue of Clinical Pharmacology & Therapeutics on the company's prototype compound, MSDC-0160, a novel once-a-day oral insulin sensitizer and the first in a new class of therapeutic agents called mTOT Modulators, showed this new generation of insulin sensitizer met the study's primary endpoint of significantly reducing fasting plasma glucose (FPG) and significantly reduced hemoglobin A1c (HbA1c). The study was a 90-day, randomized, double-blind, comparator- and placebo-controlled, multi-dose study completed in 258 patients with type 2 diabetes. The study compared three doses of MSDC-0160 (50 mg, 100 mg and 150 mg) to maximum dose Actos (pioglitazone 45 mg) or placebo taken orally once daily for 12 weeks. All treatments were well tolerated. There were no serious adverse events attributed by investigators to the MSDC drug.

Similar Private Companies By Industry

Company Name Region
IntelliGeneScan, Inc. United States
Navisonics, Inc. United States
Coserics, LLC United States
Vidus Ocular, Inc. United States
Ataxion, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Metabolic Solutions Development Company, LLC, please visit www.msdrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.